ABEONA THERAPEUTICS INC.
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $11.40M | $-0.35 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $8.70M | $-0.30 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.10 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $400.00K | $1.71 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.24 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | $-0.63 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | $-0.26 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-1.16 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | Before market open | – | – | – |
Press releases
Announcements Abeona Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics ® Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
Abeona Therapeutics® Announces Appointment of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics ® Reports Full Year 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Provides Business Update Highlighting Building Momentum in ZEVASKYN ® Commercial Launch
Other events · EX-99.1 to Form 8-K
Therapeutics ® Reports Third Quarter 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Reports Second Quarter 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Acquisition or disposition completed · Results of operations · Other events · EX-99.1 to Form 8-K
Therapeutics ® Reports First Quarter 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Enters into Agreement to Sell Priority Review Voucher for $155 Million
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic
Other events · EX-99.1 to Form 8-K
Therapeutics ® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Therapeutics ® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis
Other events · EX-99.1 to Form 8-K
Therapeutics ® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Other events · EX-99.1 to Form 8-K
Therapeutics ® Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Provides Regulatory Update on Pz-cel
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces $50 Million Credit Facility
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
Other events · EX-99.1 to Form 8-K
Abeona Therapeutics Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Other events · EX-99.1 to Form 8-K
Abeona Therapeutics Announces $25 Million Registered
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces $35 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Therapeutics Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K